AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8776638
Drug: High-dose heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose heparin management (300 IU/kg i.v. and 5,000 IU/L priming; target ACT over 480 seconds)
Trial: 6429872
Drug: Intravenous feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous feeding with amino acid dextrose solutions and fat emulsions
Trial: 31655622
Drug: Ambrisentan 5-10
RxNorm normalized name: ambrisentan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan 5-10 mg/day
Trial: 27163237
Drug: Dexamethasone 0.7
RxNorm normalized name: dexamethasone 0.7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.7 mg
Trial: 9989713
Drug: Physiotherapy Treatment
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physiotherapy Treatment (PT)
Trial: 2148341
Drug: Moclobemide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (300 mg daily in three divided doses)
Trial: 7306966
Drug: CMF (cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF (cyclophosphamide, 400 mg/sq m; methotrexate, 30 mg/sq m; and 5‐FU, 500 mg/sq m, given i.v. every 2 weeks)
Trial: 7306966
Drug: 5‐fluorouracil (5‐FU,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐fluorouracil (5‐FU, 500 mg/sq m i.v. every week)
Trial: 31551226
Drug: Carvedilol combined
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol combined with conventional therapy
Trial: 23701010
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene instruction and supragingival scaling (treatment group, n = 26)
Trial: 23701010
Drug: No periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No periodontal treatment (control group, n = 29)
Trial: 21889802
Drug: Behavior or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior or cognitive therapy (16 sessions) with fluvoxamine
Trial: 21889802
Drug: Behavior or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior or cognitive therapy (16 sessions) without fluvoxamine
Trial: 18637764
Drug: P. ginseng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P. ginseng and warfarin (n = 12)
Trial: 18637764
Drug: Warfarin only
RxNorm normalized name: Warfarin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin only (n = 13)
Trial: 10095815
Drug: Mid-morning snack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid-morning snack served 2 hours after insulin injection
Trial: 18294568
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (secondary prevention)
Trial: 18294568
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (new-onset or postoperative AF)
Trial: 6536513
Drug: Cimetidine (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (Group III: 5 mg kg‐1 orally in a.m.)
Trial: 6536513
Drug: Cimetidine (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (Group IV: 5 mg kg‐1 orally in a.m. and glycopyrrolate 5 micrograms kg‐1 in a.m.)
Trial: 6536513
Drug: Cimetidine (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (Group V: 5 mg kg‐1 orally h.s. and a.m.)
Trial: 25248854
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care presentation encouraging employers to work with their health plan to improve depression treatment quality indicators
Trial: 22752636
Drug: GFD +
RxNorm normalized name: Gluten-free diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFD + prednisolone (1 mg/kg for 4 weeks, n = 16)
Trial: 22752636
Drug: GFD +
RxNorm normalized name: Gluten-free diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFD + prednisolone (1 mg/kg for 4 weeks)
Trial: 7150496
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of fenoterol aerosol (400 micrograms)
Trial: 7150496
Drug: Buccal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal administration of fenoterol (400 micrograms)
Trial: 27871538
Drug: Dexmedetomidine 1‐μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1‐μg/kg load followed by 1‐μg/(kg h) infusion
Trial: 27871538
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 300 μg/(kg min) reduced to 250‐μg/(kg min) infusion
Trial: 24291194
Drug: HOWARU(®) Restore
RxNorm normalized name: Restone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOWARU(®) Restore probiotic 1.70×10(10) CFU (high-dose, n=168)
Trial: 24291194
Drug: HOWARU(®) Restore
RxNorm normalized name: Restone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOWARU(®) Restore probiotic 4.17×10(9) CFU (low-dose, n=168)
Trial: 12046068
Drug: Preoperative regional
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative regional artery chemotherapy (PRACT)
Trial: 10459075
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral carbohydrate administration (CHO-H)
Trial: 10459075
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral carbohydrate administration (CHO-C)
Trial: 7608279
Drug: L-Arginine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Arginine infusion (500 mg/kg over 30 min)
Trial: 2193166
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (800 mg per day)
Trial: 499288
Drug: Oral aminophylline
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral aminophylline 500 mg
Trial: 499288
Drug: Aminophylline suppository
RxNorm normalized name: aminophylline Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline suppository 500 mg
Trial: 30999952
Drug: SMS text
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS text message intervention plus Treatment As Usual (TAU) receiving nine SMS text messages at 1, 2, 3, 4, 5, 6, 8, 10 and 12 months post-discharge.
Trial: 30999952
Drug: Treatment As
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment As Usual (TAU) alone.
Trial: 27917593
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment 1
Trial: 27917593
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment 2
Trial: 25935596
Drug: Methylaminolevulinate photodynamic
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylaminolevulinate photodynamic therapy (MAL-PDT)
Trial: 25935596
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (tumors without treatment failure)
Trial: 20881878
Drug: Creatine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (5 g·d)
Trial: 19563393
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg and Simvastatin 10 mg daily (E10/S10)
Trial: 16452264
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment of medial collateral ligament injury (n = 23)
Trial: 16452264
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment of medial collateral ligament injury (n = 24)
Trial: 8972892
Drug: Captopril (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (12.5 to 50 mg twice daily)
Trial: 8972892
Drug: Beta-blockers (atenolol:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (atenolol: 25 to 100 mg once daily or propranolol: 10 to 80 mg twice daily)
Trial: 26861976
Drug: EMLA topical
RxNorm normalized name: EMLA Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA topical anaesthetic (2.5% lidocaine and 2.5% prilocaine)
Trial: 26861976
Drug: Ametop topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ametop topical anaesthetic (4% tetracaine)
Trial: 24379278
Drug: Diuretic efficiency
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic efficiency (DE) estimated as net fluid output produced per 40 mg of furosemide equivalents, dichotomized into high versus low DE.
Trial: 24379278
Drug: Traditional baseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional baseline characteristics and metrics of renal function and preadmission diuretic therapy.
Trial: 22679721
Drug: Huzhang Tongfeng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huzhang Tongfeng Granule (HTG), diclofenac sodium extended‐release capsule, Jinhuang Ointment (JO) in the acute stage; Yinlian Tongfeng Granule (YTG) and Benzbromarone Tablet (BT) in the intermission stage.
Trial: 22679721
Drug: diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: diclofenac sodium extended‐release capsule in the acute stage; Benzbromarone Tablet (BT) in the intermission stage.
Trial: 2403484
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three antibiotics (TCV)
Trial: 31830292
Drug: Topical citicoline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical citicoline eye drops three times a day for 1 month
Trial: 11430565
Drug: Prednisolone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (5 mg at 09:00 and 2.5 mg at 14:00)
Trial: 11430565
Drug: Dexamethasone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.5 mg at 23:00) with prednisolone (2.5 mg at 14:00)
Trial: 9409140
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months outpatient treatment (experimental group)
Trial: 9409140
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months outpatient treatment (experimental group)
Trial: 9409140
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (3 months treatment)
Trial: 9409140
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (6 months treatment)
Trial: 7968645
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose oral contraceptive (30 mcg ethinyl estradiol plus 75 mcg gestodene)
Trial: 30277890
Drug: Sedation, vasoactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedation, vasoactive medications, or occurrence of pneumothorax
Trial: 28350519
Drug: Other treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other treatments (MISC)
Trial: 26184525
Drug: Rilonacept (160mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilonacept (160mg intrabursal injection)
Trial: 21992986
Drug: Expedited Partner
RxNorm normalized name: Milkthistle Fruit (Silybum Marianum L. Gaertner)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expedited Partner Therapy (EPT)
Trial: 17004900
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein (25 g protein, four times a week for 4 weeks)
Trial: 14581272
Drug: Docetaxel (36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (36 mg/m²)
Trial: 14581272
Drug: Paclitaxel (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (80 mg/m²)
Trial: 8702052
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 150 mg kg‐1 in 250 ml 5% dextrose i.v. over 30 min
Trial: 8702052
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in 250 ml 5% dextrose i.v. over 30 min
Trial: 1731546
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine (100 mg IV) followed 1 min later by propofol (2 mg/kg)
Trial: 1731546
Drug: Propofol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2 mg/kg IV)
Trial: 1731546
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine administered after a tourniquet inflated to 50 mm Hg for 1 min
Trial: 6748177
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of zinc sulfate daily for eight weeks
Trial: 26278425
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg rosuvastatin daily from preoperative day 7 to postoperative day 28
Trial: 23616503
Drug: Whole-grain (WG)
RxNorm normalized name: rice (whole grain) allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-grain (WG) diet (150 g/d)
Trial: 11703246
Drug: Intravenous PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous PCA
Trial: 9104663
Drug: Intramuscular injections
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections (IM)
Trial: 8240927
Drug: (R,S)-atenolol 100
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (R,S)-atenolol 100 mg
Trial: 10335905
Drug: (R)-atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (R)-atenolol 50 mg
Trial: 10335905
Drug: (S)-atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (S)-atenolol 50 mg
Trial: 2946975
Drug: Maprotiline 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maprotiline 150 mg
Trial: 2970456
Drug: Zimelidine 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimelidine 100 mg
Trial: 6452797
Drug: Zimelidine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimelidine 200 mg
Trial: 2946975
Drug: Indalpine 25
RxNorm normalized name: Indalpine
DrugBank: Indalpine (DB08953)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indalpine 25 mg
Trial: 2946975
Drug: Indalpine 50
RxNorm normalized name: Indalpine
DrugBank: Indalpine (DB08953)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indalpine 50 mg
Trial: 31640317
Drug: Caffeine mouth
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine mouth rinse (CAF) - 25 ml of mint syrup with 1.2% of CAF, equivalent to 300 mg of CAF
Trial: 31640317
Drug: Placebo (PLA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA) - 25 ml of mint syrup without CAF
Trial: 26329293
Drug: Prednisone (PRD)
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone (PRD) 40 mg/m²/day
Trial: 26329293
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) 10 mg/kg/day with PRD
Trial: 24331154
Drug: Tecemotide (806
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tecemotide (806 μg lipopeptide) administered weekly for 8 weeks, then every 6 weeks until disease progression or withdrawal.
Trial: 24331154
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered weekly for 8 weeks, then every 6 weeks until disease progression or withdrawal.
Trial: 11777260
Drug: 15 months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 months of once‐weekly topical amorolfine lacquer + 6 weeks of oral terbinafine (250 mg once daily)
Trial: 11777260
Drug: 15 months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 months of once‐weekly topical amorolfine lacquer + 12 weeks of oral terbinafine (250 mg once daily)
Trial: 11777260
Drug: 12 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weeks of oral terbinafine (250 mg once daily)
Trial: 8510064
Drug: Conservative treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatments including drug therapy and counselling
Trial: 16230074
Drug: Entecavir 1.0
RxNorm normalized name: ENTECAVIR 1.0 mg ORAL TABLET, FILM COATED [BARACLUDE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir 1.0 mg daily
Trial: 18690353
Drug: Clopidogrel (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (600 mg loading dose followed by 75 mg daily) and Aspirin (75-325 mg daily for at least six months)
Trial: 9302132
Drug: Alprostadil injections
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprostadil injections 3 times per week for 12 weeks
Trial: 9302132
Drug: Observation without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observation without any erectogenic treatment
Trial: 9302132
Drug: Alprostadil injections
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprostadil injections
Trial: 8377686
Drug: Enteric coated
RxNorm normalized name: Mesasal Enteric Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated aspirin (100 mg daily)
Trial: 2252184
Drug: Diclofenac 75
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 75 mg intramuscularly
Trial: 22971253
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health counseling
Trial: 27504845
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health counseling and fluoride varnish
Trial: 20008946
Drug: Fluoxetine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine monotherapy (20 mg/day)
Trial: 20008946
Drug: Mirtazapine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (30 mg/day) plus Fluoxetine (20 mg/day)
Trial: 20008946
Drug: Mirtazapine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (30 mg/day) plus Venlafaxine (225 mg/day titrated in 14 days)
Trial: 20008946
Drug: Mirtazapine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (30 mg/day) plus Bupropion (150 mg/day)
Trial: 16186422
Drug: Aspirin pretreatment
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin pretreatment (1200 mg PO)
Trial: 2459540
Drug: Quinapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (10 to 40 mg twice daily, increased every 4 weeks)
Trial: 20496731
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Xinbao pills, 3 pills each time, thrice each day for 4 weeks.
Trial: 12759717
Drug: Atropine infusion
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine infusion (0.15 microg/kg/min continuously)
Trial: 12759717
Drug: Isoprenaline infusion
RxNorm normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoprenaline infusion (3.5‐35 ng/kg/min)
Trial: 12759717
Drug: Terbutaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline infusion (25‐150 ng/kg/min)
Trial: 12759717
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion (20‐160 ng/kg/min)
Trial: 10793322
Drug: Donepezil (initially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (initially 3 mg per day, increased to 5, 7, and 10 mg per day as needed)
Trial: 22047597
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) with 670-nm laser irradiation, 40 mW, 1.6 J, 2.04 J/cm(2), 51 mW/cm(2) per blister in the prodromal stage and 4.8 J in the crust and secondarily infected stages, plus 1.2 J at the C2-C3 vertebrae
Trial: 22047597
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy including acyclovir cream or tablets
Trial: 15842517
Drug: Placebo (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (120 mg three times daily)
Trial: 11742909
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (BDP), 1,000 microg/d for 4 months
Trial: 11742909
Drug: Inhaled bronchodilator
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled bronchodilator therapy (control group)